Open AccessEfficacy of teriparatide in patients with hypoparathyroidism: A prospective, open-label study
Author(s) -
Vimal Upreti,
Shrikant Somani,
Narendra Kotwal
Publication year - 2017
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_340_16
Subject(s) - alfacalcidol , medicine , hypoparathyroidism , parathyroid hormone , vitamin d and neurology , calcitriol , hypocalcaemia , hydrochlorothiazide , urinary calcium , adverse effect , context (archaeology) , prospective cohort study , secondary hyperparathyroidism , endocrinology , urology , osteoporosis , calcium , bone mineral , blood pressure , paleontology , biology
Conventional treatment of hypoparathyroidism with calcium, Vitamin D analogs, and thiazide diuretics is often suboptimal, and these patients have poor quality of life. Teriparatide (parathyroid hormone 1-34 [PTH (1-34)]), an amide of PTH, is widely available for the use in osteoporosis; however, its use in hypoparathyroidism is limited.